* 香港和黄医药0013.HK周一早盘升2.2%。
* 该公司稍早公告称，启动全球首创的抗体靶向偶联药物--HMPL-A830用于治疗不可切除的晚期或转移性实体瘤的全球临床试验的Ia期部分。首名患者已于2026年9月24日于中国接受首次给药治疗。
* 和黄医药今年迄今涨8.3%，同期恒生指数.HSI下滑3.6%。
* 恒⽣⽣物科技指数.HSBIO盘中一度跌1.1%。（完）
更多股市简讯请点选CN-CMN-HOT
* 香港和黄医药0013.HK周一早盘升2.2%。
* 该公司稍早公告称，启动全球首创的抗体靶向偶联药物--HMPL-A830用于治疗不可切除的晚期或转移性实体瘤的全球临床试验的Ia期部分。首名患者已于2026年9月24日于中国接受首次给药治疗。
* 和黄医药今年迄今涨8.3%，同期恒生指数.HSI下滑3.6%。
* 恒⽣⽣物科技指数.HSBIO盘中一度跌1.1%。（完）
更多股市简讯请点选CN-CMN-HOT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.